


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (GH-161)	MILVEXIAN
PRONUNCIATION	mil vex' i an
THERAPEUTIC CLAIM	Prevention and treatment of thromboembolic disorders

CHEMICAL NAMES

1. 11,15-Metheno-15*H*-pyrazolo[4,3-*b*][1,7]diazacyclotetradecin-5(6*H*)-one, 10-[4-[5-chloro-2-(4-chloro-1*H*-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6*H*)-pyrimidinyl]-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6*R*,10*S*)-
2. (5*R*,9*S*)-9-(4-(5-chloro-2-(4-chloro-1*H*-1,2,3-triazol-1-yl)phenyl)-6-oxopyrimidin-1(6*H*)-yl)-2¹-(difluoromethyl)-5-methyl-2¹*H*-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclonaphan-4-one

STRUCTURAL FORMULA



MOLECULAR FORMULA	C ₂₈ H ₂₃ Cl ₂ F ₂ N ₉ O ₂
MOLECULAR WEIGHT	626.4
TRADEMARK	None as yet
SPONSOR	Bristol-Myers Squibb Company and Janssen Pharmaceuticals
CODE DESIGNATIONS	BMS 986177, JNJ-70033093
<u>CAS</u> REGISTRY NUMBER	1802425-99-5
UNII	0W79NDQ608
WHO NUMBER	11401

gbk